EP0667779A1 - Ophthalmische lösung und verfahren zu ihrer verwendung - Google Patents

Ophthalmische lösung und verfahren zu ihrer verwendung

Info

Publication number
EP0667779A1
EP0667779A1 EP93925100A EP93925100A EP0667779A1 EP 0667779 A1 EP0667779 A1 EP 0667779A1 EP 93925100 A EP93925100 A EP 93925100A EP 93925100 A EP93925100 A EP 93925100A EP 0667779 A1 EP0667779 A1 EP 0667779A1
Authority
EP
European Patent Office
Prior art keywords
solution
dermatan sulfate
eye
molecular weight
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93925100A
Other languages
English (en)
French (fr)
Inventor
Jeffrey S. Kiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
CytRx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CytRx Corp filed Critical CytRx Corp
Publication of EP0667779A1 publication Critical patent/EP0667779A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
    • A61L12/141—Biguanides, e.g. chlorhexidine
    • A61L12/142—Polymeric biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
    • A61L12/124—Hydrogen peroxide; Peroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
    • A61L12/143—Quaternary ammonium compounds
    • A61L12/145—Polymeric quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates to methods and compositions which are useful in a wide variety of ocular applications.
  • the present invention is a solution containing dermatan sulfate and is particularly useful as a contact lens washing and storing solution.
  • the present invention is also useful as an eye wash during eye surgery and also includes an eye shield for corneal surgery.
  • tear film and debris consisting of proteinaceous, oily, sebaceous, and related organic matter have a tendency to deposit and build up on lens surfaces.
  • contact lenses must be cleaned to remove these tear film deposits and debris. If these deposits are not properly removed, both the wetability and optical clarity of the lenses is substantially reduced causing discomfort for the wearer.
  • contact lenses especially those made from hydrophilic materials, must be continuously disinfected to kill any harmful microorganisms that may be present or grow on the lenses.
  • a number of methods for disinfecting contact lenses have been used such as the use of high temperatures, the use of oxidative chemicals, and the use of antimicrobial agents.
  • current disinfecting solutions do not exhibit significant cleaning ability for the removal of proteinaceous material.
  • cleaners Conventionally, the cleaning of contact lenses is accomplished with one or both of two general classes of cleaners.
  • Surfactant cleaners generally known as “daily cleaners” because of their recommended daily use, are effective for the removal of most carbohydrate and lipid derived matter. However, they are not as effective for the removal of proteinaceous matter such as lysozyme.
  • proteolytic enzymes derived from plant, animal, and microbial sources are used to remove the proteinaceous deposits.
  • enzyme cleaners are recommended for weekly use and are conventionally employed by dissolving enzyme tablets in suitable aqueous solutions.
  • the process of cleaning and disinfecting contact lenses with enzyme cleaners involves two steps.
  • the first step consists of the cleaning phase whereby lenses are conventionally soaked in an enzyme cleaning solution at ambient temperature conditions, i.e., cold soaking for a period of up to 12 hours, to achieve effective removal of proteinaceous deposits.
  • the lenses are separately disinfected. Disinfection involves contacting the lenses with a solution containing either an oxidative chemical or an antimicrobial agent at ambient temperatures or exposing the lenses to elevated temperatures for specified periods of time. The latter disinfection technique requires specific electrical disinfecting apparatus.
  • contact lenses fall into two categories: the hard or rigid corneal type lenses formed from materials prepared by polymerization of acrylic esters, such as polymethyl methacrylate (PMMA), and gel, hydrogel or soft type lenses made of polymerized hydrophilic or hydrophobic monomers, such as 2-hydroxyethyl methacrylate (HEMA).
  • PMMA polymethyl methacrylate
  • HEMA 2-hydroxyethyl methacrylate
  • Soft type contact lenses and certain of the gas permeable hard contact lenses also have a tendency to bind and concentrate significantly more fluids, environmental pollutants, water impurities as well as antimicrobial agents and other active ingredients commonly found in lens care solutions. In most instances, the low levels of the ingredients in lens care solutions do not lead to eye tissue irritation when used properly. Nevertheless, because of the inherent binding action of protein deposits, disinfecting agents and preservatives, deposits tend to build up on lens surfaces and become concentrated to potentially hazardous levels, such that, when released, can cause corneal inflammation and other eye tissue irritation.
  • chlorhexidine a biguanide
  • benzalkonium chloride binds to soft lens material seven times less than benzalkonium chloride, but the presence of proteinaceous oily tear-film deposits can double the amount of chlorhexidine absorbed over that of clean tissue.
  • U.S. Pat. No. 4,354,952 discloses very dilute disinfecting and cleaning solutions containing chlorhexidine or its salts in combination with certain amphoteric and non-ionic surfactants. These solutions were found to reduce the amount of binding of chlorhexidine on hydrophilic soft contact lenses.
  • other disinfecting and preservative agents that are being used for contact lenses include polyaminopropyl biguanide, Onomer M, hydrogen peroxide and sorbic acid.
  • ophthalmic solutions include eye rewetting and lubrication drops, eye washes, eye ointments, eye shields, dissolvable eye inserts and interocular eye gels or fluids. The solutions are all designed to provide comfort and/or protection for the eye. Ophthalmic drug products that have been approved for over-the-counter human use are summarized in the final monograph under 21 CFR Part 349 which is incorporated herein by reference.
  • U.S. Patent No. 5,141,928 discloses the use of glycosaminoglycan polysulfates with a molecular weight of between 5,000 and 20,000 daltons for ophthalmic medications in the prevention and treatment of eye injuries.
  • glycosaminoglycans of this molecular weight tend to be relatively unstable. They do not withstand heat sterilization and will break down in the presence of oxidants such as hydrogen peroxide.
  • glycosaminoglycans of this molecular weight which include hyaluronic acid, are difficult to sterilize by filtration.
  • the solution should have lubricating qualities that reduce eye irritation and provide increased comfort after application of the solution to the eye.
  • the lubricating components in the solutions should be resistant to breakdown during sterilization and should be resistant to breakdown in the presence of disinfecting agents.
  • the present invention provides for improved solutions and methods for disinfecting, storing and/or inserting contact lenses into the eye.
  • the solutions and methods are compatible with both hard and soft type lenses, both tinted and untinted, and are adaptable for use with virtually any of the commonly known disinfecting techniques, including "cold" soaking under ambient temperature conditions, as well as with high temperature disinfecting methods.
  • the present invention also includes solutions and compositions which can be used for a wide variety of ophthamic uses such as eye rewetting drops, lubrication drops, eye washes, eye ointments, eye shields, dissolvable eye insets and interocular eye gels or fluids.
  • the present invention includes solutions which contain dermatan sulfate or glycosaminoglycans with physical properties similar to dermatan sulfate.
  • the preferred concentration of dermatan sulfate in the wash and soaking solutions is between approximately 0.01% and 5% by weight.
  • the molecular weight range of dermatan sulfate is between 5,000 and 100,000 daltons with the preferred molecular weight of the dermatan sulfate being between approximately 25,000 and 60,000 daltons.
  • the present invention also includes saline wash solutions for contact lenses which contain dermatan sulfate. These solutions can optionally contain surfactants which will enhance the cleaning activity of the solution. Because of the presence of the dermatan sulfate in the solution, the cleaning solution has lubricating properties and the ability to reduce ocular irritation.
  • the present invention also includes eye drops that contain dermatan sulfate.
  • These eye drops can optionally include antihistamines, vasoconstrictors and/or other active ingredients.
  • the drops can be used to soothe eye strain or can be used to alleviate strain or irritation due to the presence of contact lenses.
  • Eye drops containing dermatan sulfate according to the present invention have a lubricating quality that makes the drops ideal for treating dry eyes.
  • the drops made and used according to the present invention reduce irritation due to allergens or medications.
  • Another embodiment of the present invention is the addition of dermatan sulfate to over-the-counter eye drops and prescription eye drops.
  • the addition of dermatan sulfate to these products increases the product's effectiveness in providing eye comfort. With irritating active ingredients in many pharmaceutical formulations, dermatan sulfate provides reduced irritation to the eyes and better overall tolerance.
  • dermatan sulfate solutions can be sterilized by autoclaving or filtration, a wide variety of single and multi-use products containing dermatan sulfate are contemplated as being included in the present invention.
  • disinfecting components such as hydrogen peroxide can be added to the solution providing a disinfecting solution which has desirable lubricating properties.
  • cross-linking agents such as cyanuric chloride, glutaraldehyde, hexamethylene diisocyanate or hexanoic anhydride, an ocular shield can be made which is useful in ocular surgery.
  • the ocular shield is made up of between 80% and 100% crosslinked dermatan sulfate.
  • the cross-linked dermatan sulfate can also be used to deliver drugs to eye tissues.
  • the cross-linked dermatan sulfate can be impregnated with a desired drug, such as an anti-glaucoma drug, and then placed under the eyelid thereby delivering the drug to the eye over a period of time. Accordingly, it is an object of the present invention to provide an improved ocular solution for use as eye drops, contact lens cleaning solution and contact lens storage solution. It is another object of the present invention to provide a lubricating solution that can be sterilized by methods including, but not limited to, heat, filtration, or radiation.
  • the present invention comprises a wide variety of solutions, ointments and creams for use in ocular applications.
  • the present invention includes solutions, ointments and creams that contain dermatan sulfate.
  • the solutions and compositions can include other active components such as antibiotics, disinfectants, vasoconstrictors and/or antihistamines.
  • the present invention also includes solutions which can be used with contact lenses. These solutions are useful with either hard contact lenses, gas permeable contact lenses or soft contact lenses. These solutions include, but are not limited to, solutions for washing contact lenses, solutions for disinfecting contact lenses, and solutions for inserting the contact lenses into the eye.
  • Another embodiment of the present invention is the incorporation of dermatan sulfate into an aqueous based gel, salve or ointment. The gel can also be nonaqueous based. The gel or ointment can then be applied to the eye or to eye tissues.
  • Dermatan sulfate ( ⁇ -L-iduronosyl-(l-3)- ⁇ -D-N- acytylgalactosamine 4-sulfate) is classified as a glycosaminoglycan sulfate.
  • Dermatan sulfate consists of repeating disaccharide units of iduronosyl and acetylgalactosamine. It can be isolated from various tissues including blood vessel walls, lungs and skin. There are minor differences in the structure of dermatan sulfate depending upon from which tissue the compound is isolated. These differences in structure are primarily attributed to differences in the degree of sulfation.
  • the present invention includes dermatan sulfates from all sources, including natural sources or from recombinant methods. Dermatan compounds generally are weak anticoagulants. The preferred form of dermatan sulfate is highly sulfated. The silver, copper or zinc salts of dermatan sulfate can be used to impart microbiocidal activity to the dermatan sulfate solutions.
  • An important aspect of the present invention is the molecular weight of the dermatan sulfate.
  • Dermatan sulfate is a polymer and is therefore made up of a population of molecules of different sizes having an overall average molecular weight.
  • the present invention includes various solutions with dermatan sulfate that has a molecular weight of between approximately 5,000 to 100,000 with a preferred molecular weight of between 25,000 and 60,000 daltons. The most preferred molecular weight of dermatan sulfate is between approximately 30,000 and 45,000 daltons.
  • Pharmaceutically acceptable vehicles that can carry the dermatan sulfate at the preferred concentrations include, but are not limited to, aqueous and nonaqueous solutions, gels, ointments, suspensions, and aerosols.
  • the solutions may by isotonic, hypotonic, or hypertonic and can include a variety of pharmaceutically acceptable salts, including but not limited to,
  • the vehicle may also contain surfactants, chelating agents, such as EDTA, and a variety of buffers well known to those of ordinary skill in the art.
  • One embodiment of the present invention is an aqueous solution of dermatan sulfate.
  • the optimal concentration of dermatan sulfate will depend upon the application that is contemplated. For example, for the saline solution for use as eye drops, the preferred concentration of dermatan sulfate in saline is between approximately 0.01% to 3% with the most preferred concentration of dermatan sulfate in saline of between approximately 0.05% to 1%.
  • saline a solution of sodium chloride, containing 0.9% by weight of sodium chloride in 1000 cc of water
  • other solutions, either isotonic or not isotonic can be used in preparing the eye drops according to the present invention.
  • Dermatan sulfate is not toxic to the sensitive tissues that make up the eye.
  • dermatan sulfate has unique wetting and lubricating qualities that make it particularly useful in inserting and wearing contact lenses. Because dermatan sulfate is resistant to breakdown by heat, solutions containing dermatan sulfate can be heat sterilized. These solutions can also be sterilized by filtration. This is a particular advantage over prior art preparations that use other glycosaminoglycans such as those disclosed in U.S. Patent No. 5,141,928. The glycosaminoglycans disclosed in the '928 patent cannot be sterilized by heat and are difficult to filter sterilize.
  • the present invention is particularly useful for the preparation of compositions or liquid baths for the storage of hard or soft contact lenses including the soft, hydratable, permeable contact lenses, contact lenses which are oxygen permeable, such as the hydroxy ethylmethacrylate contact lenses, and the non- hydrated or non-hydratable lenses, including the hydrophobic silicone lenses. It is believed that, because the dermatan sulfate has a net negative charge, it retards the adherence of protein from the eye on contact lenses. Thus, the dermatan sulfate solution according to the present invention reduces the adherence of protein and other substances on the lens thereby reducing die cloudy build ⁇ up on the lens. It is contemplated as part of the present invention that enzymes such as proteases can be added to the dermatan sulfate solution.
  • Another advantage of the contact lens solutions made according to the present invention is the capability of adding disinfecting agents to the solution. It has been determined that the dermatan sulfate in the solution according to the present invention is resistant to breakdown by disinfecting agents which may be required to disinfect the contact lenses.
  • a common disinfecting agent used to treat contact lenses is hydrogen peroxide. While a system utilizing hydrogen peroxide is effective in disinfecting contact lenses, the hydrogen peroxide also reacts with other components in the solution. Because the dermatan sulfate is resistant to breakdown by hydrogen peroxide, the disinfecting solution with the dermatan sulfate not only kills or inhibits microbial growth, but also has desirable lubricating qualities required of a contact lens solution.
  • the present invention also includes eye drops for alleviating eye strain, dry eye, allergies or for treating irritation due to allergies or medication.
  • the preferred concentration of dermatan sulfate for these solutions is between approximately 0.05% to 5% by weight in saline.
  • Other components such as demulcents, emollients, vasconstrictors and decongestants can be used with dermatan sulfate.
  • Demulcents are soothing substances which relieve pain or irritation in mucus membranes.
  • Demulcents which are suitable for use with dermatan sulfate in the ophthalmic solutions according to the present invention include, but are not limited to, cellulose derivatives such as sodium carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and methylcellulose.
  • demulcents that can be used in the present invention are dextran, gelatin, polyols, glycerin, polyethylene glycol 300, polyethylene glycol 400, polysorbate, propylene glycol, polyvinyl alcohol and povidone.
  • Ophthalmic emollients that can be used with dermatan sulfate according to the present invention include, but are not limited to, lanolin, light mineral oil, paraffin, petrolatum, white ointment, white petrolatum, white wax or yellow wax.
  • Ophthalmic vasoconstrictors that can be used with dermatan sulfate include, but are not limited to, ephedrine hydrochloride, phenylephrine hydrochloride, tetrahydroxoline hydrochloride.
  • the present invention is particularly useful as an eyewash for eye strain or eye irritation because of the lubricating and wetting properties of the solution due to the presence of the dermatan sulfate.
  • Another embodiment of the present invention includes cross-linked dermatan sulfate for use as a corneal shield.
  • the shield can also have active agents incorporated therein which will be slowly released as the shield breaks down.
  • the shield can be 100% dermatan sulfate or can be a mixture of components such as a mixture of dermatan sulfate and collagen.
  • the cross-linked dermatan sulfate is acted upon by enzymes in the body fluids and gradually breaks down as the tissue heals.
  • a drug such as an anti-glaucoma drug
  • a drug can be incorporated into the cross-linked dermatan sulfate and then shaped into a small plug or other appropriate shape.
  • the dermatan sulfate plug can be placed under an eyelid and, as the plug breaks down, the drug is slowly delivered to the eye.
  • a solution for use as eye drops or as a solution for storing contact lenses is prepared by dissolving 1 gram of dermatan sulfate isolated from porcine lung (Scientific Protein Labs,
  • Waunakee, WS Waunakee, WS is dissolved in 1 liter of saline. The solution is then sterilized at 121°C for 30 minutes. The solution is then applied to the eyes of a patient to reduce irritation in the eye.
  • the contact lenses When used as a contact lens soaking solution, the contact lenses are immersed and stored in the solution until use.
  • the eye drop solution has the following components: Component Amount
  • the eye drops are applied to the eye every four hours until the eyes are normal.
  • the eye drop solution has the following components:
  • the eye drops are applied to the eye every four hours until the eyes are normal.
  • the contact lenses are soaked in the solution for 12 hours after use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP93925100A 1992-10-28 1993-10-28 Ophthalmische lösung und verfahren zu ihrer verwendung Withdrawn EP0667779A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96761192A 1992-10-28 1992-10-28
US967611 1992-10-28
US13248493A 1993-10-06 1993-10-06
US132484 1993-10-06
PCT/US1993/010352 WO1994009794A1 (en) 1992-10-28 1993-10-28 Ophthalmic solution and method of use

Publications (1)

Publication Number Publication Date
EP0667779A1 true EP0667779A1 (de) 1995-08-23

Family

ID=26830403

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93925100A Withdrawn EP0667779A1 (de) 1992-10-28 1993-10-28 Ophthalmische lösung und verfahren zu ihrer verwendung

Country Status (5)

Country Link
EP (1) EP0667779A1 (de)
JP (1) JPH08503701A (de)
AU (1) AU5454594A (de)
CA (1) CA2148108A1 (de)
WO (1) WO1994009794A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518732A (en) * 1995-02-14 1996-05-21 Chiron Vision, Inc. Bio-erodible ophthalmic shield
JPH09206362A (ja) * 1996-02-05 1997-08-12 Tomey Technol Corp コンタクトレンズ用消毒洗浄組成物及びそれを用いたコンタクトレンズの消毒洗浄方法
GB2323180A (en) * 1997-01-23 1998-09-16 Waverley Pharma Ltd Hydrogen peroxide contact lens solution
JP3883739B2 (ja) * 1998-05-22 2007-02-21 株式会社メニコン コンタクトレンズ用殺菌液
TW586945B (en) 2001-01-12 2004-05-11 Novartis Ag Lens care product containing dexpanthenol
KR20070114130A (ko) 2005-02-14 2007-11-29 존슨 앤드 존슨 비젼 케어, 인코포레이티드 착용감이 편안한 안용 장치 및 이의 제조방법
TW200722109A (en) * 2005-03-31 2007-06-16 Bausch & Lomb Polysaccharide and polyol composition for treating dry eye and related methods of manufacture and methods of use
US9052529B2 (en) 2006-02-10 2015-06-09 Johnson & Johnson Vision Care, Inc. Comfortable ophthalmic device and methods of its production
TWI551305B (zh) 2007-08-31 2016-10-01 諾華公司 相對黏稠封裝溶液之用途
US8689971B2 (en) 2007-08-31 2014-04-08 Novartis Ag Contact lens packaging solutions
JP6595120B2 (ja) 2015-12-03 2019-10-23 ノバルティス アーゲー コンタクトレンズパッケージング溶液

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9409794A1 *

Also Published As

Publication number Publication date
CA2148108A1 (en) 1994-05-11
WO1994009794A1 (en) 1994-05-11
JPH08503701A (ja) 1996-04-23
AU5454594A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
EP0371728B1 (de) Wässrige Augenlösung und Verfahren zur Konservierung derselben
EP0929292B1 (de) Verfahren und zusammensetzung zur wiederbenetzung von kontaktlinsen und linderung der augentrockenheit
ES2374607T3 (es) Composiciones oftálmicas con un tensioactivo anfótero y ácido hialurónico.
US4046706A (en) Contact lens cleaning composition
EP1347787B1 (de) Verwendung von Dexpanthenol in Kontaktlinsenpflegezusammensetzungen
CA2431719C (en) Prevention of preservative uptake into biomaterials
JP5543346B2 (ja) カルボキシル修飾されたフルクタンまたはその塩を含む眼科用組成物
US6528464B1 (en) Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels
EP1641472A2 (de) Synergistische antimikrobielle ophthalmische und dermatologische zubereitungen mit chlorit- und wasserstoffperoxid
EP0667779A1 (de) Ophthalmische lösung und verfahren zu ihrer verwendung
KR100348237B1 (ko) 콘택트렌즈의소독·중화·세정용일액형조합제제및소독·중화·세정방법
JPH0368503A (ja) コンタクトレンズ用液剤
CN104136005A (zh) 含有烷氧基化天然蜡的眼科组合物
WO1990006126A1 (en) Disinfectant compositions for ophthalmic devices
KR19990074047A (ko) 콘택트렌즈용 세척, 소독 및 보존제 조성물
Ghormley Ultracare™—disinfectant/neutralizer
HK1021619B (en) Method and composition for rewetting contact lenses and relieving eye dryness
HK1005164B (en) Aqueous ophthalmic solutions and method for preserving same
HK1059945B (en) Prevention of preservative uptake into ophthalmic lences

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950428

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KIEL, JEFFREY S.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970501